Dr. Denham on Hyperprogression in Patients With NSCLC

Claude Denham, MD
Published: Tuesday, Feb 20, 2018



Claude Denham, MD, Baylor Medical Center, discusses the manifestation of hyperprogression in patients with non–small cell lung cancer (NSCLC) who have been treated with immunotherapy.

When asked whether there is enough research on hyperprogression in patients treated with immunotherapy to warrant concern, Denham explains that he has observed it, and that it is not fully understood by the oncology community. Denham recalled a patient in which he saw the trajectory of their cancer change markedly after their first dose of immunotherapy.

Hyperprogression in patients treated with immune agents is rare, but one of the challenges physicians have in patients with lung cancer is that many of them have a lot of smoking-related co-morbidities that make separating out the more non-specific inflammatory events of immune therapy with hyperprogression or autoimmune-related adverse events somewhat complicated.
 


Claude Denham, MD, Baylor Medical Center, discusses the manifestation of hyperprogression in patients with non–small cell lung cancer (NSCLC) who have been treated with immunotherapy.

When asked whether there is enough research on hyperprogression in patients treated with immunotherapy to warrant concern, Denham explains that he has observed it, and that it is not fully understood by the oncology community. Denham recalled a patient in which he saw the trajectory of their cancer change markedly after their first dose of immunotherapy.

Hyperprogression in patients treated with immune agents is rare, but one of the challenges physicians have in patients with lung cancer is that many of them have a lot of smoking-related co-morbidities that make separating out the more non-specific inflammatory events of immune therapy with hyperprogression or autoimmune-related adverse events somewhat complicated.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x